USA: In a recent exposure-matched study, researchers found that long-term exposure to fine particulate matter (PM2.5) may ...

UK-based pharmaceutical company GSK has reported positive outcomes from two Phase III trials of depemokimab for treating ...

The China National Medical Products Administration (NMPA) has approved GSK’s Nucala (mepolizumab) as an add-on treatment with intranasal corticosteroids to treat chronic rhinosinusitis with ...

Simultaneously, the three regulators are also reviewing a second potential indication for depemokimab as an add-on therapy for chronic rhinosinusitis with nasal polyps (CRSwNP). GSK has said ...

Researchers have developed and preliminarily tested a composite score that simultaneously assesses the severity of asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) in patients with both ...

AZ is hoping that Fasenra (benralizumab) could join rival drugs from Sanofi/Regeneron and GlaxoSmithKline as approved therapies for chronic rhinosinusitis with nasal polyps (CRSwNP) that have been ...

These quiz questions about chronic rhinosinusitis with nasal polyps (CRSwNP) are derived from current literature. Are you up to date? At the end of the quiz, compare your score with those of your ...

Several possible mechanisms have been proposed, including microbes (bacteria, fungi, viruses), biofilm formation, staphylococcal superantigen (most often associated with CRSwNP), osteitis and ...

NUCALA is used to treat severe eosinophilic asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and eosinophilic granulomatosis with polyangiitis (EGPA). For more information, see Section 1.

Corticosteroid Reduction. Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of OMLYCLO therapy for asthma or CRSwNP. Eosinophilic Conditions. Be alert to eosinophilia, ...

In addition to COPD, Dupixent is approved in Japan in certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis (CRSwNP), prurigo nodularis and chronic ...